Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study

Authors: Hagop M. Kantarjian, Daniel J. DeAngelo, Anjali S. Advani, Matthias Stelljes, Partow Kebriaei, Ryan D. Cassaday, Akil Merchant, Naohito Fujishima, Toshiki Uchida, María Calbacho, Anna Ejduk, Susan O’Brien, Elias Jabbour, Hui Zhang, Barbara Sleight, Erik Vandendries, David I. Marks - The Lancet 2017 cited by 212